Used in bioconjugation processes, particularly in antibody-drug conjugates (ADCs), where it serves as a linker component to connect cytotoxic agents to monoclonal antibodies. Its polyethylene glycol (PEG)-based structure enhances solubility and improves pharmacokinetic properties of the conjugate. The terminal functional groups allow for selective attachment to both the antibody and the drug payload, enabling controlled release in targeted cancer therapies. This compound contributes to increased stability in circulation and reduced off-target toxicity, making it valuable in the design of next-generation therapeutic conjugates.